Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Cwm LLC

Cwm LLC lifted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 82.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,241 shares of the company’s stock after purchasing an additional 1,918 shares during the quarter. Cwm LLC’s holdings in Medpace were worth $1,416,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Rise Advisors LLC purchased a new stake in Medpace during the 1st quarter valued at about $27,000. Mather Group LLC. acquired a new stake in Medpace in the 1st quarter valued at $28,000. Fidelis Capital Partners LLC purchased a new stake in shares of Medpace during the first quarter worth about $31,000. J.Safra Asset Management Corp increased its stake in shares of Medpace by 87.0% during the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after purchasing an additional 47 shares in the last quarter. Finally, DT Investment Partners LLC acquired a new position in shares of Medpace during the 2nd quarter worth about $41,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on MEDP. UBS Group lowered Medpace from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $420.00 to $350.00 in a research note on Friday, September 27th. Guggenheim dropped their target price on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. William Blair reissued an “outperform” rating on shares of Medpace in a research note on Wednesday, September 11th. Finally, Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and cut their target price for the stock from $415.00 to $345.00 in a research note on Wednesday, September 25th. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $394.00.

Medpace Trading Down 0.1 %

Shares of NASDAQ:MEDP opened at $353.30 on Wednesday. The business has a 50-day moving average price of $358.25 and a 200 day moving average price of $384.34. Medpace Holdings, Inc. has a 12-month low of $227.21 and a 12-month high of $459.77. The company has a market capitalization of $10.95 billion, a price-to-earnings ratio of 36.01, a PEG ratio of 1.77 and a beta of 1.35.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.54 by $0.21. The business had revenue of $528.10 million for the quarter, compared to the consensus estimate of $528.41 million. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The business’s revenue was up 14.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.93 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 11.64 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.